

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 March 2022 (03.03.2022)



(10) International Publication Number
WO 2022/047031 A1

(51) International Patent Classification:

C07D 495/20 (2006.01) C07D 519/00 (2006.01)
A61P 13/12 (2006.01) A61K 31/438 (2006.01)

(21) International Application Number:

PCT/US2021/047754

(22) International Filing Date:

26 August 2021 (26.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/070,705 26 August 2020 (26.08.2020) US

(71) Applicant: VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(72) Inventors: AHN, Jun Myun; 50 Northern Avenue, Boston, Massachusetts 02210 (US). ANGLE, Samantha; 50 Northern Avenue, Boston, Massachusetts 02210 (US). BRODNEY, Michael Aaron; 50 Northern Avenue, Boston, Massachusetts 02210 (US). CAO, Jingrong; 50 Northern Avenue, Boston, Massachusetts 02210 (US). COCHRAN, John E.; 50 Northern Avenue, Boston, Massachusetts 02210 (US). COME, Jon H.; 50 Northern Avenue, Boston, Massachusetts 02210 (US). DAKIN, Leslie A.; 50 Northern Avenue, Boston, Massachusetts 02210 (US). DOLGIKH, Elena; 50 Northern Avenue, Boston, Massachusetts 02210 (US). MAXWELL, Brad D.; 50 Northern Avenue, Boston, Massachusetts 02210 (US). NANTHAKUMAR, Suganthini S.; 50 Northern Avenue, Boston, Massachusetts 02210 (US). O'DOWD, Hardwin; 50 Northern Avenue, Boston, Massachusetts 02210 (US). OLSEN, Jessica Howard; 50 Northern Avenue, Boston, Massachusetts 02210 (US). SENTER, Timothy J.; 50 Northern Avenue, Boston, Massachusetts 02210 (US). SHIMIZU, Akira Joseph; 50 Northern Avenue, Boston, Massachusetts 02210 (US). STONE, Steven David; 50 Northern Avenue,

Boston, Massachusetts 02210 (US). WANG, Haoxuan; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(74) Agent: MCDONELL, Leslie A. et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: INHIBITORS OF APOL1 AND METHODS OF USING SAME



I

(57) Abstract: The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).

WO 2022/047031 A1